Abpro utilizes two proprietary technology platforms, DiversImmune® and MultiMab™, to develop next-generation antibody therapies aimed at treating severe and life-threatening diseases. The DiversImmune® platform focuses on generating high-affinity and high-specificity antibodies that can effectively target challenging therapeutic areas. In contrast, the MultiMab™ platform is designed to engineer these antibodies into various bi- and multi-specific formats, enhancing their efficacy and safety. This combination of platforms allows Abpro to create a diverse pipeline of therapeutic candidates that can address a wide range of human diseases, particularly in the field of immuno-oncology.

One of the key innovations in Abpro's approach is the TetraBi antibody format, which is a tetravalent bispecific design that enables bivalent binding to tumor-associated antigens. This format is engineered to improve the therapeutic window by selectively activating T cells in the presence of tumor cells, thereby enhancing the potential for effective treatment while minimizing off-target effects. The TetraBi format also incorporates Fc modifications to reduce toxicity and extend the antibody's half-life, making it a promising candidate for future therapies targeting various cancers and other conditions. Through these advanced technologies, Abpro aims to develop therapies that not only improve patient outcomes but also address the limitations of existing treatments.

United States

Abpro Corporation is a biotech company developing next-generation antibody therapies. Established in 1897, Abpro offers competitive salaries and generous benefits with the opportunity to learn and grow in an employee-driven culture. They are focused on developing antibody therapies to improve the lives of patients facing severe and life-threatening diseases.

Abpro

Company Details